From the Research
The treatment of Extramembranous Glomerulonephritis (EMGN) should prioritize a combination of immunosuppressive therapy and supportive care, with the goal of reducing proteinuria, preserving kidney function, and minimizing morbidity and mortality. The most recent and highest quality study on this topic is not directly provided in the given evidence, but based on the available information, the treatment approach can be guided by the principles of managing glomerulonephritis in general.
- For patients with EMGN, the initial approach may involve conservative management with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) to control blood pressure and reduce proteinuria, as suggested by general practices in nephrology 1.
- For those with more severe disease or persistent proteinuria, immunosuppressive therapy may be indicated, with options including corticosteroids, cyclophosphamide, and calcineurin inhibitors, as discussed in various studies on glomerulonephritis treatment 2, 3, 4.
- The use of biologic agents, such as rituximab, may also be considered in certain cases, especially where there is a need for more targeted immunosuppression with potentially fewer side effects, as explored in recent reviews on the treatment of glomerulonephritides 5.
- Supportive care, including diuretics for edema, statins for hyperlipidemia, and anticoagulation for patients at risk for thromboembolism, should be tailored to the individual patient's needs and risk factors.
- Regular monitoring of proteinuria, serum albumin, and kidney function is crucial to adjust therapy and ensure the best possible outcomes in terms of morbidity, mortality, and quality of life.